Is atomoxetine a stimulant?

No. Atomoxetine is a non-stimulant medication — it's a selective noradrenaline reuptake inhibitor, working through a different mechanism from amphetamine-type or methylphenidate-type stimulants.

Is atomoxetine a controlled drug?

No, atomoxetine is not a controlled drug in the UK, unlike the stimulant ADHD medications. It's still prescription-only, but doesn't carry the same controlled-drug legal restrictions.

How long does atomoxetine take to work?

Unlike stimulants, which can act within hours, atomoxetine typically takes several weeks of consistent daily use to reach its full effect. Some people notice partial improvement earlier, but full benefit takes longer to assess.

Who is atomoxetine usually prescribed for?

It's often considered for people who can't take stimulant medication (due to certain health conditions or contraindications), don't respond well to stimulants, or have a history that makes a non-controlled medication preferable — though it can be an appropriate first choice for some people too.

What are common side effects of atomoxetine?

Commonly reported effects include nausea, reduced appetite, fatigue, and dry mouth, particularly when starting treatment. Your prescriber will monitor for these and can adjust dosing to help manage them.

Atomoxetine (Strattera): UK ADHD Medication Guide

Atomoxetine, sold as Strattera, is a non-stimulant ADHD medication licensed for use in the UK. It works differently from stimulant options like methylphenidate or lisdexamfetamine, and isn't a controlled drug.

What it is and how it's used

Atomoxetine treats ADHD in children, adolescents and adults by increasing noradrenaline availability in the brain, which is thought to improve attention regulation and impulse control, though through a different mechanism from stimulant medications. It's taken daily, usually once or split into two doses, and its full effect builds gradually rather than appearing immediately.

Medication class and mechanism

Atomoxetine is a selective noradrenaline reuptake inhibitor (SNRI) — it blocks the reuptake of noradrenaline at the synapse, increasing its availability, without the direct dopamine-release mechanism associated with stimulant medications. This is why it's classified as a non-stimulant, despite treating the same underlying condition.

UK brand and formulation

Sold in the UK as Strattera, available in capsule form across a range of strengths, with dosing adjusted gradually (titrated) based on body weight (in children) and response.

Prescription status in the UK

Atomoxetine is prescription-only but is not a Controlled Drug under UK misuse-of-drugs legislation, unlike the stimulant ADHD medications. It's available on the NHS and privately, following formal ADHD diagnosis, the same as any other ADHD medication.

Common considerations

Atomoxetine typically needs several weeks of consistent use before its full effect is clear — this is a normal part of treatment, not a sign it isn't working.
Because it isn't a controlled drug, it doesn't carry the same prescribing/dispensing restrictions as stimulant options, which some people and prescribers find practically simpler.
It's often considered when stimulant medication isn't suitable — due to certain cardiovascular conditions, a history of substance misuse, or previous stimulant side effects — though it can also be chosen as a first option based on individual assessment.
Nausea and reduced appetite are common when starting, and often improve over the following weeks.

Safety and warnings

Atomoxetine carries its own specific precautions, including monitoring for mood changes (particularly early in treatment) and liver function in some cases. As with any prescription medication, it should only be started, stopped or dose-adjusted under medical supervision, and any concerning symptoms should be reported to your prescriber promptly.

Starting treatment

Because atomoxetine builds up gradually, its starting dose is usually held for a period before being increased, rather than adjusted week to week the way stimulant doses sometimes are. Your prescriber will typically check in during the first weeks to review side effects like nausea or appetite changes, and again around the point where full effect is expected, to assess whether it's working and whether the dose needs adjusting. It's worth planning for this longer run-in period rather than expecting an immediate result.

How it fits into UK ADHD treatment

Atomoxetine is one of two non-stimulant options licensed for UK ADHD treatment, alongside guanfacine. See our guanfacine medication page for the other non-stimulant option, or the ADHD medication overview for how atomoxetine compares to the UK's stimulant medications.

Source: EMC — Strattera SmPC.

Atomoxetine (Strattera): UK ADHD Medication Information